A meta-analysis of RCTs and cohort studies showed that SGLT2 inhibitors reduce the risk of AKI across diverse cardiovascular risk profiles [59,109], and are associated with lower mortality, major adverse kidney events, and MACE in acute kidney disease [110]
Understanding these potential pathways helps contextualize the limited available evidence and identify areas requiring further investigation
For comprehensive weight loss support If you want medication plus lifestyle coaching, nutrition guidance, behavioral support, and ongoing medical monitoring, look at platforms like Calibrate, Found, or Sequence
Prime the Pen Dial a small amount and release to remove air
The focus here is on realistic, actionable guidance
Similar content being viewed by others Log in or create a free account to read this content Gain free access to this article, as well as selected content from this journal and more on nature.com or References Graa X, Reddy EP